tesaglitazar has been researched along with Insulin Resistance in 10 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 8 (80.00) | 29.6817 |
| 2010's | 2 (20.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Hamrén, B; Karlsson, MO; Ribbing, J; Svensson, MK | 1 |
| Farkouh, M; Plutzky, J; Rosenson, RS; Wright, RS | 1 |
| Bamberg, K; Camejo, G; Dahllöf, B; Kjellstedt, A; Ljung, B; Oakes, ND; Ostling, J; Svensson, L | 1 |
| Cooney, GJ; Furler, SM; Hegarty, BD; Kraegen, EW; Oakes, ND | 1 |
| Camejo, G; Hultstrand, T; Jacinto, S; Ljung, B; Oakes, ND; Thalén, P; Wallin, B | 1 |
| Cox, SL | 1 |
| Boesten, LS; Camejo, G; Emeis, JJ; Havekes, LM; Jukema, JW; Kooistra, T; Lundholm, E; van Vlijmen, BJ; Zadelaar, AS | 1 |
| Anzalone, D; Goldstein, BJ; Ohman, KP; Rosenstock, J; Tou, C | 1 |
| Birketvedt, GS; Edwards, S; Fagerberg, B; Gause-Nilsson, I; Halldórsdóttir, S; Halmos, T; Lopatynski, J; Ohman, KP; Schuster, H; Stender, S; Tonstad, S | 1 |
| Birketvedt, GS; Fagerberg, B; Gause-Nilsson, I; Ohman, KP; Schuster, H; Tonstad, S | 1 |
2 review(s) available for tesaglitazar and Insulin Resistance
| Article | Year |
|---|---|
Modulating peroxisome proliferator-activated receptors for therapeutic benefit? Biology, clinical experience, and future prospects.
Topics: Alkanesulfonates; Diabetic Angiopathies; Glycine; Humans; Hypoglycemic Agents; Insulin Resistance; Ligands; Oxazines; Oxazoles; Phenylpropionates; Phosphorylation; PPAR alpha; PPAR delta; PPAR gamma; Thiazolidinediones; Thiophenes; United States; United States Food and Drug Administration | 2012 |
Tesaglitazar: a promising approach in type 2 diabetes.
Topics: Alkanesulfonates; Animals; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Dyslipidemias; Humans; Insulin Resistance; Phenylpropionates; PPAR alpha; PPAR gamma | 2006 |
3 trial(s) available for tesaglitazar and Insulin Resistance
| Article | Year |
|---|---|
Effect of tesaglitazar, a dual PPAR alpha/gamma agonist, on glucose and lipid abnormalities in patients with type 2 diabetes: a 12-week dose-ranging trial.
Topics: Adult; Aged; Aged, 80 and over; Alkanesulfonates; Blood Glucose; Cholesterol, HDL; Cholesterol, VLDL; Diabetes Mellitus, Type 2; Female; Glycated Hemoglobin; Humans; Insulin Resistance; Lipids; Male; Middle Aged; Phenylpropionates; PPAR alpha; PPAR gamma | 2006 |
Tesaglitazar, a dual peroxisome proliferator-activated receptor alpha/gamma agonist, improves apolipoprotein levels in non-diabetic subjects with insulin resistance.
Topics: Adult; Aged; Alkanesulfonates; Apolipoprotein A-I; Apolipoprotein C-III; Apolipoproteins; Apolipoproteins B; Cholesterol, LDL; Dose-Response Relationship, Drug; Dyslipidemias; Female; Humans; Insulin Resistance; Male; Middle Aged; Phenylpropionates; PPAR alpha; PPAR gamma | 2008 |
Improvement of postprandial lipid handling and glucose tolerance in a non-diabetic population by the dual PPARalpha/gamma agonist, tesaglitazar.
Topics: Adult; Alkanesulfonates; Blood Glucose; Double-Blind Method; Female; Glucose Tolerance Test; Humans; Hyperglycemia; Insulin Resistance; Lipids; Male; Middle Aged; Phenylpropionates; Postprandial Period; PPAR alpha; PPAR gamma; Triglycerides | 2007 |
5 other study(ies) available for tesaglitazar and Insulin Resistance
| Article | Year |
|---|---|
A model for glucose, insulin, and beta-cell dynamics in subjects with insulin resistance and patients with type 2 diabetes.
Topics: Alkanesulfonates; Blood Glucose; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Diabetes Mellitus, Type 2; Fasting; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Insulin-Secreting Cells; Models, Biological; Peroxisome Proliferator-Activated Receptors; Phenylpropionates; Predictive Value of Tests; Time Factors | 2010 |
AZ 242, a novel PPARalpha/gamma agonist with beneficial effects on insulin resistance and carbohydrate and lipid metabolism in ob/ob mice and obese Zucker rats.
Topics: Alkanesulfonates; Animals; Bezafibrate; Carbohydrate Metabolism; Cinnamates; Diabetes Mellitus; Fatty Acids; Glucose; Humans; Insulin Resistance; Lipid Metabolism; Male; Mass Spectrometry; Mice; Mice, Obese; Molecular Structure; Obesity; Phenylpropionates; Rats; Rats, Zucker; Receptors, Cytoplasmic and Nuclear; Transcription Factors; Tumor Cells, Cultured | 2002 |
Peroxisome proliferator-activated receptor (PPAR) activation induces tissue-specific effects on fatty acid uptake and metabolism in vivo--a study using the novel PPARalpha/gamma agonist tesaglitazar.
Topics: Adipose Tissue; Alkanesulfonates; Animals; Cinnamates; Dietary Fats; Fatty Acids, Nonesterified; Insulin; Insulin Resistance; Liver; Male; Muscle, Skeletal; Phenylpropionates; Rats; Rats, Wistar; Receptors, Cytoplasmic and Nuclear; Transcription Factors | 2004 |
Tesaglitazar, a dual PPAR{alpha}/{gamma} agonist, ameliorates glucose and lipid intolerance in obese Zucker rats.
Topics: Administration, Oral; Alkanesulfonates; Animals; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Glucose; Insulin Resistance; Lipid Metabolism; Lipids; Liver; Metabolic Syndrome; Obesity; Phenylpropionates; PPAR alpha; PPAR gamma; Rats; Rats, Zucker; Treatment Outcome; Triglycerides | 2005 |
Dual PPARalpha/gamma agonist tesaglitazar reduces atherosclerosis in insulin-resistant and hypercholesterolemic ApoE*3Leiden mice.
Topics: Alkanesulfonates; Animals; Apolipoprotein E3; Apolipoproteins E; Atherosclerosis; Biomarkers; Blood Vessels; Cell Adhesion; Cholesterol; Cholesterol, Dietary; Collagen; Dietary Fats; Female; Hypercholesterolemia; Inflammation; Insulin Resistance; Lipids; Lipoproteins; Macrophages; Mice; Mice, Transgenic; Monocytes; NF-kappa B; Phenylpropionates; PPAR alpha; PPAR gamma | 2006 |